<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">United European Gastroenterol J</journal-id>
<journal-id journal-id-type="iso-abbrev">United European Gastroenterol J</journal-id>
<journal-id journal-id-type="publisher-id">UEG</journal-id>
<journal-id journal-id-type="hwp">spueg</journal-id>
<journal-title-group>
<journal-title>United European Gastroenterology Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">2050-6406</issn>
<issn pub-type="epub">2050-6414</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31065364</article-id>
<article-id pub-id-type="pmc">6488795</article-id>
<article-id pub-id-type="doi">10.1177/2050640619836057</article-id>
<article-id pub-id-type="publisher-id">10.1177_2050640619836057</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Celiac disease-on-chip: Modeling a multifactorial disease in
vitro</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moerkens</surname>
<given-names>Renée</given-names>
</name>
<xref ref-type="aff" rid="aff1-2050640619836057">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mooiweer</surname>
<given-names>Joram</given-names>
</name>
<xref ref-type="aff" rid="aff1-2050640619836057">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Withoff</surname>
<given-names>Sebo</given-names>
</name>
<xref ref-type="aff" rid="aff1-2050640619836057">1</xref>
<xref ref-type="corresp" rid="corresp1-2050640619836057"></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-5635-1614</contrib-id>
<name>
<surname>Wijmenga</surname>
<given-names>Cisca</given-names>
</name>
<xref ref-type="aff" rid="aff1-2050640619836057">1</xref>
<xref ref-type="aff" rid="aff2-2050640619836057">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2050640619836057"><label>1</label>Department of Genetics, University
Medical Center Groningen, University of Groningen, Groningen, the Netherlands</aff>
<aff id="aff2-2050640619836057"><label>2</label>K.G. Jebsen Coeliac Disease Research
Center, Department of Immunology, University of Oslo, Norway</aff>
<author-notes>
<fn fn-type="equal" id="fn1-2050640619836057">
<p>Review was written by R.M. and J.M., these authors contributed equally.</p>
</fn>
<corresp id="corresp1-2050640619836057">S. Withoff, University Medical Center
Groningen, Department of Genetics, Hanzeplein 1, Groningen, 9713GZ, the
Netherlands. Email: <email>s.withoff@umcg.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>7</volume>
<issue>4</issue>
<fpage>467</fpage>
<lpage>476</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© Author(s) 2019</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder content-type="society">United European
Gastroenterology</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons
Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by/4.0/">http://www.creativecommons.org/licenses/by/4.0/</ext-link>) which
permits any use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE
and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Conventional model systems cannot fully recapitulate the multifactorial character
of complex diseases like celiac disease (CeD), a common chronic intestinal
disorder in which many different genetic risk factors interact with
environmental factors such as dietary gluten. However, by combining recently
developed human induced pluripotent stem cell (hiPSC) technology and
organ-on-chip technology, in vitro intestine-on-chip systems can now be
developed that integrate the genetic background of complex diseases, the
different interacting cell types involved in disease pathology, and the
modulating environmental factors such as gluten and the gut microbiome. The
hiPSCs that are the basis of these systems can be generated from both diseased
and healthy individuals, which means they can be stratified based on their load
of genetic risk factors. A CeD-on-chip model system has great potential to
improve our understanding of disease etiology and accelerate the development of
novel treatments and preventive therapies in CeD and other complex diseases.</p>
</abstract>
<kwd-group>
<kwd>Celiac disease</kwd>
<kwd>complex diseases</kwd>
<kwd>organ-on-chip</kwd>
<kwd>hiPSCs</kwd>
<kwd>human induced pluripotent stem cells</kwd>
<kwd>microfluidic devices</kwd>
</kwd-group>
<funding-group>
<award-group id="award1-2050640619836057">
<funding-source id="funding1-2050640619836057">
<institution-wrap>
<institution>European Research Council Advanced Grant</institution>
<institution-id institution-id-type="FundRef"></institution-id>
</institution-wrap>
</funding-source>
<award-id rid="funding1-2050640619836057">FP7/2007-2013/ERC Advanced Grant
Agreement 2012-32</award-id>
</award-group>
<award-group id="award2-2050640619836057">
<funding-source id="funding2-2050640619836057">
<institution-wrap>
<institution>PhD scholarship from the Graduate School of Medical
Sciences, University of Groningen</institution>
<institution-id institution-id-type="FundRef"></institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="award3-2050640619836057">
<funding-source id="funding3-2050640619836057">
<institution-wrap>
<institution>Nederlandse Organisatie voor Wetenschappelijk
Onderzoek</institution>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003246</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="funding3-2050640619836057">024.003.001</award-id>
<award-id rid="funding3-2050640619836057">NWO SPI 92-266</award-id>
</award-group>
<award-group id="award4-2050640619836057">
<funding-source id="funding4-2050640619836057">
<institution-wrap>
<institution>United European Gastroenterology (UEG) Research Prize
2018</institution>
<institution-id institution-id-type="FundRef"></institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="sec1-2050640619836057" sec-type="intro">
<title>Introduction</title>
<p>Approximately 0.6% to 1%<sup><xref ref-type="bibr" rid="bibr1-2050640619836057">1</xref></sup> of the Caucasian population has celiac disease (CeD), a complex
immune-mediated disease characterized by a strong inflammatory reaction to dietary
gluten in genetically predisposed individuals. CeD is a multifactorial disease
caused by many genetic and environmental risk factors. In addition to gluten, viral
infections<sup><xref ref-type="bibr" rid="bibr2-2050640619836057">2</xref>,<xref ref-type="bibr" rid="bibr3-2050640619836057">3</xref></sup>
and gut microbiome dysbiosis<sup><xref ref-type="bibr" rid="bibr4-2050640619836057">4</xref></sup> may also trigger disease onset. Although CeD is primarily characterized by
damage to the small intestine, patients can also suffer from extraintestinal
manifestations such as anemia, osteoporosis and ataxia.<sup><xref ref-type="bibr" rid="bibr5-2050640619836057">5</xref>,<xref ref-type="bibr" rid="bibr6-2050640619836057">6</xref></sup> The large variation in
presentation of symptoms leaves many patients undiagnosed.<sup><xref ref-type="bibr" rid="bibr7-2050640619836057">7</xref>,<xref ref-type="bibr" rid="bibr8-2050640619836057">8</xref></sup> After diagnosis, the only
treatment is lifelong adherence to a gluten-free diet, which can reduce quality of life<sup><xref ref-type="bibr" rid="bibr9-2050640619836057">9</xref></sup> and may not totally prevent gluten exposure because of “hidden” sources of
gluten or cross-contamination of food products.</p>
<p>To better understand the natural course of CeD and design new preventive and
treatment strategies, it is imperative to develop sophisticated systems that
recapitulate and model the disease. Such systems have not been available thus far,
but with recent molecular and technological advances—specifically in human induced
pluripotent stem cell (hiPSC) technology, differentiation protocols and
organ-on-chip devices—these complex modeling systems are now within reach. In this
review we illustrate the complexity of CeD and describe how state-of-the-art stem
cell and organ-on-chip technology can provide an in vitro model for CeD.</p>
<sec id="sec2-2050640619836057">
<title>Pathogenesis of CeD</title>
<sec id="sec3-2050640619836057">
<title>Immune response to gluten</title>
<p>The main trigger of CeD-associated inflammation is dietary gluten, a storage
protein present in wheat, barley and rye. Gluten proteins are rich in
glutamine and proline residues that are difficult to digest.<sup><xref ref-type="bibr" rid="bibr10-2050640619836057">10</xref></sup> As a consequence, incompletely digested gluten peptides pass the
epithelial layer of the small intestine<sup><xref ref-type="bibr" rid="bibr11-2050640619836057">11</xref></sup> and enter the lamina propria where the peptide fragments are
deamidated by tissue transglutaminase 2 (TG2; <xref ref-type="fig" rid="fig1-2050640619836057">Figure 1</xref>). Deamidated gluten peptides
have a higher affinity to class II human leukocyte antigen (HLA)-DQ2 or -DQ8
molecules on antigen-presenting cells (APCs).<sup><xref ref-type="bibr" rid="bibr12-2050640619836057">12</xref>,<xref ref-type="bibr" rid="bibr13-2050640619836057">13</xref></sup> APCs presenting
deamidated gluten peptides strongly activate gluten-specific CD4 + T cells,
which further elicit the pro-inflammatory response characteristic of CeD.
This response drives B cell-mediated generation of TG2- and gluten-specific
antibodies that are used to diagnose CeD,<sup><xref ref-type="bibr" rid="bibr13-2050640619836057">13</xref></sup> and licenses CD8 + intraepithelial lymphocytes (IELs) to kill
intestinal epithelial cells (IECs) leading to villous atrophy.<sup><xref ref-type="bibr" rid="bibr14-2050640619836057">14</xref></sup> Key cytokines in these processes are interferon-gamma,<sup><xref ref-type="bibr" rid="bibr12-2050640619836057">12</xref></sup> interleukin (IL)-15<sup>14</sup> and IL-21.<sup><xref ref-type="bibr" rid="bibr15-2050640619836057">15</xref></sup>
<fig id="fig1-2050640619836057" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Schematic overview of celiac disease (CeD) pathobiology. Dietary
gluten peptides pass the epithelial barrier, where they become
deamidated by tissue transglutaminase 2 (TG2). The deamidated
gluten peptides are taken up by antigen presenting cells (APCs)
and are presented to CD4<sup>+</sup> T cells, exclusively in the
context of human leukocyte antigen (HLA)-DQ2 or HLA-DQ8. Upon
gluten presentation, CD4<sup>+</sup> T cells produce, among
other things, interleukin (IL)-21 and interferon-gamma (IFN-γ).
This leads to gluten-specific antibody production by B cells
and, in concert with IL-15 production by intestinal epithelial
cells (IECs), activation of intraepithelial lymphocytes (IELs),
which attack the IECs, leading to villous atrophy.</p></caption><graphic xlink:href="10.1177_2050640619836057-fig1"></graphic></fig></p>
</sec>
<sec id="sec4-2050640619836057">
<title>Genetic factors</title>
<p>Today, approximately 50% of the heritability of CeD can be explained by 45
genetic risk factors (Ricaño-Ponce et al., manuscript in preparation). The
major genetic risk factors for CeD development are specific variants of the
HLA class II genes (HLA-DQ2.5, HLA-DQ2.2 and HLA-DQ8), and carriership is
essential but not sufficient to trigger the disease.<sup><xref ref-type="bibr" rid="bibr16-2050640619836057">16</xref></sup> Genome-wide association studies (GWAS) have identified 44 non-HLA
risk factors, many of which are shared with other immune-related diseases
(e.g. type 1 diabetes, rheumatoid arthritis, ulcerative colitis and Crohn
disease).<sup><xref ref-type="bibr" rid="bibr17-2050640619836057">17</xref>,<xref ref-type="bibr" rid="bibr18-2050640619836057">18</xref></sup> Most of these risk factors point to genes involved
in immune response and are expressed in different types of immune cells.<sup><xref ref-type="bibr" rid="bibr19-2050640619836057">19</xref></sup> However, a subset of the genes are expressed in the intestinal barrier,<sup><xref ref-type="bibr" rid="bibr20-2050640619836057">20</xref></sup> suggesting that barrier dysfunction plays a role in CeD.</p>
</sec>
<sec id="sec5-2050640619836057">
<title>Environmental factors and the microbiome</title>
<p>Because not all carriers of genetic risk for CeD manifest the disease,
non-genetic environmental factors apart from gluten may also play a role in
disease onset. One such environmental factor might be the amylase trypsin
inhibitors (ATIs) present in gluten-containing grains, because these can
trigger a Toll-like receptor 4-dependent innate immune response in the small intestine.<sup><xref ref-type="bibr" rid="bibr21-2050640619836057">21</xref></sup> Additionally, viral infections (by rotaviruses, adenovirus,
enteroviruses and hepatitis C virus) are associated with increased incidence
of CeD.<sup><xref ref-type="bibr" rid="bibr22-2050640619836057">22</xref>,<xref ref-type="bibr" rid="bibr23-2050640619836057">23</xref></sup> Interestingly, a significant number of
CeD-associated genetic loci harbor transcription factor binding elements for
gene products of the Epstein-Barr virus, indicating one way that viruses can
regulate CeD-associated pathways.<sup><xref ref-type="bibr" rid="bibr3-2050640619836057">3</xref></sup> One of the few published experimental studies showed that reovirus
infections can disrupt tolerance to gluten and other food antigens in
HLA-DQ8–expressing mice.<sup><xref ref-type="bibr" rid="bibr2-2050640619836057">2</xref></sup></p>
<p>Furthermore, the gut microbiome composition is altered in CeD
patients,<sup><xref ref-type="bibr" rid="bibr24-2050640619836057">24</xref><xref ref-type="bibr" rid="bibr25-2050640619836057"></xref>–<xref ref-type="bibr" rid="bibr26-2050640619836057">26</xref></sup> which could be due to genetic and environmental
factors. On the one hand, the HLA-DQ2 genotype introduces a selective
pressure on the developing intestinal microbiome in infants.<sup><xref ref-type="bibr" rid="bibr27-2050640619836057">27</xref></sup> On the other, a gluten-free diet changes the microbiome composition
of the intestine both in healthy adults and adult CeD patients.<sup><xref ref-type="bibr" rid="bibr28-2050640619836057">28</xref>,<xref ref-type="bibr" rid="bibr29-2050640619836057">29</xref></sup> These
changes in gut microbial composition can directly affect processing of
gluten peptides.<sup><xref ref-type="bibr" rid="bibr30-2050640619836057">30</xref>,<xref ref-type="bibr" rid="bibr31-2050640619836057">31</xref></sup> For example, CeD-associated bacteria can produce
shorter gluten peptides that more easily translocate across the intestinal
epithelial barrier, or modify peptides so that they activate gluten-specific
T cells.<sup><xref ref-type="bibr" rid="bibr4-2050640619836057">4</xref></sup> Additionally, changes in the gut microbiome induced by other
environmental factors (such as antibiotic use, intestinal infections and
cesarean delivery) may indirectly contribute to CeD.<sup><xref ref-type="bibr" rid="bibr25-2050640619836057">25</xref></sup> Whether the microbiome is cause or consequence in CeD and how
dysbiosis of the microbiome contributes to CeD are not clear.</p>
</sec>
<sec id="sec6-2050640619836057">
<title>Role of the intestinal barrier in CeD</title>
<p>It has been suggested that intestinal barrier function is altered in
CeD,<sup><xref ref-type="bibr" rid="bibr32-2050640619836057">32</xref><xref ref-type="bibr" rid="bibr33-2050640619836057"></xref>–<xref ref-type="bibr" rid="bibr34-2050640619836057">34</xref></sup> but it has been a matter of debate whether destruction
of the barrier is only a consequence of the inflammatory immune response, or
whether there is a primary defect in barrier function that contributes to
disease development.<sup><xref ref-type="bibr" rid="bibr11-2050640619836057">11</xref></sup> Several observations, including genetic associations,<sup><xref ref-type="bibr" rid="bibr18-2050640619836057">18</xref>,<xref ref-type="bibr" rid="bibr20-2050640619836057">20</xref></sup>
suggest a primary barrier defect. CeD patients as well as their relatives
have a higher lactulose:mannitol ratio in their urine after intake of this
sugar solution when compared with control individuals and patients with
aspecific gastrointestinal symptoms.<sup><xref ref-type="bibr" rid="bibr32-2050640619836057">32</xref></sup> It has also been reported that the morphology of tight junctions is
altered in the epithelial barrier of children with active CeD, and this is
only partly restored on a gluten-free diet.<sup><xref ref-type="bibr" rid="bibr35-2050640619836057">35</xref></sup> This is consistent with a report describing altered expression and
localization of epithelial tight junction proteins in CeD patients on a
gluten-free diet.<sup><xref ref-type="bibr" rid="bibr36-2050640619836057">36</xref></sup> Lastly, quantitative measures of barrier function, such as
transepithelial electrical resistance (TEER), are decreased in biopsies of
active CeD patients compared with healthy individuals, and this was only
partially restored on gluten-free diet.<sup><xref ref-type="bibr" rid="bibr11-2050640619836057">11</xref></sup></p>
</sec>
</sec>
<sec id="sec7-2050640619836057">
<title>Current models for CeD</title>
<p>To date, there is no model system that fully recapitulates the complexity of CeD.
Current in vitro models include immortalized cell lines and mucosal biopsies.
The immune system has been investigated using cell lines of monocytes, such as
THP-1, or intestinally derived T cells.<sup><xref ref-type="bibr" rid="bibr37-2050640619836057">37</xref>,<xref ref-type="bibr" rid="bibr38-2050640619836057">38</xref></sup> Existing data on
epithelial barrier function are largely based on intestinal mucosal biopsies or
Caco-2, a tetraploid human colonic epithelial cancer cell line. Immortalized
cell lines do not represent the genetics of CeD and have poor genomic integrity
(<xref ref-type="table" rid="table1-2050640619836057">Table 1</xref>).
Patient-derived intestinal biopsy material does contain the CeD-associated
genetic background and directly reflects the disease phenotype, but is scarce
because of its invasive nature. Biopsies also have limited proliferative
capacity, and individual cell types are difficult to study within a
heterogeneous biopsy. Conventional systems to measure barrier function and
transport, like transwell systems, do not recapitulate the intestinal physiology
(e.g. IECs fail to form villus-like structures or produce mucus), and
co-cultures with microbial cells are difficult in these static systems because
of rapid overgrowth and contamination.<sup><xref ref-type="bibr" rid="bibr39-2050640619836057">39</xref></sup> Studying CeD in vivo is dependent on humanized mouse models that express
human HLA-DQ8 or HLA-DQ2.<sup><xref ref-type="bibr" rid="bibr40-2050640619836057">40</xref><xref ref-type="bibr" rid="bibr41-2050640619836057"></xref>–<xref ref-type="bibr" rid="bibr42-2050640619836057">42</xref></sup> These models have shown
that the presence of gluten-specific CD4 + T cells is not sufficient to induce
CeD-like pathogenesis and that triggers of the innate immune system,
particularly IL-15 overexpression, are essential for inducing intestinal damage
upon gluten exposure. However, mice are not ideal models because of differences
in intestinal tract physiology,<sup><xref ref-type="bibr" rid="bibr43-2050640619836057">43</xref></sup> immune system<sup><xref ref-type="bibr" rid="bibr44-2050640619836057">44</xref></sup> and microbiome composition.<sup><xref ref-type="bibr" rid="bibr45-2050640619836057">45</xref></sup> To further elucidate the mechanisms underlying CeD, it is essential to
capture the entire pathobiology of CeD using multicellular and human-based
models. <table-wrap id="table1-2050640619836057" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Possible biological systems for modeling complex diseases: advantages
and disadvantages.</p></caption><alternatives><graphic specific-use="table1-2050640619836057" xlink:href="10.1177_2050640619836057-table1"></graphic><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th colspan="1" rowspan="2">Biological system</th><th colspan="5" rowspan="1">Critical factors for modeling complex
diseases<hr/></th><th colspan="1" rowspan="2">Other advantages (+) and disadvantages
(–)</th></tr><tr><th colspan="1" rowspan="1">Patient genetics</th><th colspan="1" rowspan="1">Availability of material</th><th colspan="1" rowspan="1">Genetic engineering</th><th colspan="1" rowspan="1">Heterogeneity/ complexity</th><th colspan="1" rowspan="1">Can be combined with other cell types from same donor<sup><xref ref-type="table-fn" rid="table-fn1-2050640619836057">a</xref></sup></th></tr></thead><tbody align="left" valign="top"><tr><td colspan="1" rowspan="1">Immortalized cell lines</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">High</td><td colspan="1" rowspan="1">Established</td><td colspan="1" rowspan="1">Single cell type</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">+ Potentially easier to handle − Poor genomic
integrity</td></tr><tr><td colspan="1" rowspan="1">Intestinal biopsy</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Low<sup><xref ref-type="table-fn" rid="table-fn2-2050640619836057">b</xref></sup></td><td colspan="1" rowspan="1">Difficult</td><td colspan="1" rowspan="1">Multiple cell types</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">+ Disease phenotype − Inflamed tissue − Limited
lifespan</td></tr><tr><td colspan="1" rowspan="1">Humanized mouse models</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">High</td><td colspan="1" rowspan="1">Established</td><td colspan="1" rowspan="1">Multiple cell types</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">+ Whole organism: presence of hormone, neurologic, and
metabolic signals from other organs or cell systems −
Requires thorough understanding of induction of disease
− Difficult to translate to humans because of
interspecies differences in physiology, pharmacology and
cellular processes</td></tr><tr><td colspan="1" rowspan="1">Induced pluripotent stem cells</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">High</td><td colspan="1" rowspan="1">Established</td><td colspan="1" rowspan="1">Single cell type</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">+ Suitable for genotype selection (patient and control
cases) − Requires knowledge of differentiation to
relevant tissue</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2050640619836057"><label>a</label><p>Providing identical genetic background.</p></fn><fn id="table-fn2-2050640619836057"><label>b</label><p>Invasive procedure necessary, extremely limited “healthy” control
samples.</p></fn></table-wrap-foot></table-wrap></p>
</sec>
</sec>
<sec id="sec8-2050640619836057">
<title>Novel technologies that allow CeD-on-chip</title>
<p>Novel advances in human stem cell biology and microfluidics technology now allow for
the development of in vitro model systems with the desired genetic background,
environmental factors, and interaction between disease-relevant cell types under
physiological conditions.</p>
<sec id="sec9-2050640619836057">
<title>hiPSC and organoid technology</title>
<p>hiPSCs can be generated from different types of somatic cells taken from any
donor. hiPSCs can divide indefinitely and have the potential to differentiate
into any of the cell types found in the human body. In 2006, Yamanaka and
colleagues demonstrated for the first time that human and mouse fibroblasts
could be reprogrammed to a pluripotent state, resembling embryonic cells in
culture.<sup><xref ref-type="bibr" rid="bibr46-2050640619836057">46</xref>,<xref ref-type="bibr" rid="bibr47-2050640619836057">47</xref></sup> Pluripotency was achieved by viral overexpression of only
four transcription factors: Oct4, Sox2, Klf4 and c-Myc. With the development of
improved protocols, hiPSC lines can now be efficiently generated from
urine-derived epithelial cells and blood-derived erythroblasts, among others.<sup><xref ref-type="bibr" rid="bibr48-2050640619836057">48</xref></sup></p>
<p>Using knowledge on embryonic development, hiPSCs can be differentiated into human
intestinal organoids (HIOs): miniature parts of the gut that are cultured in a
dish. The first HIOs were grown from intestinal crypts derived from human biopsy material.<sup><xref ref-type="bibr" rid="bibr49-2050640619836057">49</xref></sup> When cultured in an extracellular matrix (ECM) gel in the presence of
specific growth factors, it is possible to maintain the stem cell niche and the
proliferative and differentiation capacity of crypt cells in vitro, allowing
them to grow out into complex three-dimensional (3D) “budding” structures. These
structures contain multiple functional IEC subtypes that can be kept in culture
for prolonged periods of time.<sup><xref ref-type="bibr" rid="bibr50-2050640619836057">50</xref></sup> The generation of HIOs from hiPSCs is more complex and leads to a less
mature differentiated phenotype.<sup><xref ref-type="bibr" rid="bibr51-2050640619836057">51</xref></sup> However, embryonal development of intestinal tissue can be mimicked by
exposing hiPSCs to a series of specific growth factors in a strict
time-dependent manner.<sup><xref ref-type="bibr" rid="bibr52-2050640619836057">52</xref></sup></p>
<p>The HIO system still has limitations when it comes to studying multifactorial
diseases.<sup><xref ref-type="bibr" rid="bibr53-2050640619836057">53</xref>,<xref ref-type="bibr" rid="bibr54-2050640619836057">54</xref></sup> HIOs are inconsistent in size and shape and are cultured in
a static system (embedded in extracellular matrix) that does not recapitulate
the intestine's physical environment (including fluid flow and peristaltic
movement). The closed configuration of HIOs renders them less ideal for studying
transport over the intestinal barrier or interactions with commensal microbes or
pathogens (<xref ref-type="fig" rid="fig2-2050640619836057">Figure 2</xref>).
Apical access can be achieved by microinjection,<sup><xref ref-type="bibr" rid="bibr55-2050640619836057">55</xref></sup> but this technique is labor intensive and technically challenging. The
wide range of organoid sizes complicates this procedure even more and makes it
nearly impossible to standardize the cell:stimulus ratio. Additionally, dead
cells accumulate in the enclosed lumen of the HIO, ultimately impairing the
viability of the system. Lastly, physiological interactions with other
components of the intestine (e.g. immune and vascular system) are difficult to
emulate within the extracellular matrix, while the matrix is necessary to
generate and maintain HIOs. These limitations can be overcome by an
organ-on-chip system. <fig id="fig2-2050640619836057" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Limitations of the intestinal organoid system. Intestinal organoids
are inconsistent in size and shape, which introduces variability in
the results (see left panel). The closed configuration makes it
technically challenging to access the lumen (apical side) of the
organoids. This limits studies into interactions between intestinal
epithelial cells and micro-organisms (such as commensal microbes or
pathogens), studies into transepithelial transport (e.g. fluorescein
isothiocyanate-dextran translocation as a measure of intestinal
permeability) and analysis of luminally secreted components (see
middle panel). Intestinal organoids are cultured in a static
three-dimensional system as they are embedded in an extracellular
matrix, which does not reflect the dynamic environment of the human
intestine (see right panel).</p></caption><graphic xlink:href="10.1177_2050640619836057-fig2"></graphic></fig></p>
</sec>
<sec id="sec10-2050640619836057">
<title>Intestine-on-chip</title>
<p>Organ-on-chip systems are microfluidic devices in which cells are cultured in
continuously perfused microchannels engineered to mimic the physical
microenvironment of tissues and organs.<sup><xref ref-type="bibr" rid="bibr53-2050640619836057">53</xref></sup> A current model makes use of a chip containing two parallel hollow
channels approximately 1 mm wide separated by a porous ECM-coated membrane<sup><xref ref-type="bibr" rid="bibr56-2050640619836057">56</xref></sup> (<xref ref-type="fig" rid="fig3-2050640619836057">Figure 3</xref>). In
this device, a monolayer of IECs can be grown on the upper surface of the
membrane separating both channels, while endothelial cells can be grown on the
other side, representing blood vessels. The culture media for the cells is
delivered via the upper and lower channel, which can also be used to introduce
metabolites, cytokines, microbial cells and/or immune cells into the system. The
system also provides mechanical forces to simulate the physical microenvironment
of the intestine through fluid flow that introduces shear stress on the cells
and two vacuum compartments on the sides that create a peristalsis-like motion.
Remarkably, these mechanical forces induce epithelial cells to spontaneously
form polarized 3D villus-like structures that contain cells expressing markers
characteristic of differentiated IECs (i.e. adsorptive enterocytes,
mucus-producing goblet, Paneth and enteroendocrine cells).<sup><xref ref-type="bibr" rid="bibr39-2050640619836057">39</xref>,<xref ref-type="bibr" rid="bibr57-2050640619836057">57</xref><xref ref-type="bibr" rid="bibr58-2050640619836057"></xref>–<xref ref-type="bibr" rid="bibr59-2050640619836057">59</xref></sup> The resulting epithelial
layer exhibits basic functional properties, such as mucus production, high
barrier resistance, activity of brush border and drug-metabolizing enzymes, and
high efficiency in nutrient uptake because of the increased intestinal surface.
These characteristics allow for studies focusing on digestion and nutrient
uptake, barrier integrity and drug metabolism,<sup><xref ref-type="bibr" rid="bibr39-2050640619836057">39</xref>,<xref ref-type="bibr" rid="bibr57-2050640619836057">57</xref>,<xref ref-type="bibr" rid="bibr58-2050640619836057">58</xref></sup> and for co-cultures with
commensal microbial cells for extended periods of time (up to weeks).<sup><xref ref-type="bibr" rid="bibr39-2050640619836057">39</xref>,<xref ref-type="bibr" rid="bibr60-2050640619836057">60</xref></sup>
<fig id="fig3-2050640619836057" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Schematic presentation of a microengineered intestine-on-chip.
Intestine-on-chip systems often consist of a top microfluidic
channel, resembling the gut lumen, and a bottom microfluidic
channel, resembling the lamina propria and vasculature. The channels
are separated by a porous membrane on which epithelial cells can be
seeded and are flanked by vacuum chambers to simulate
peristalsis-like movements. Unidirectional fluid flow through the
microfluidic channels and contractions of the vacuum chambers
simulate the physical microenvironment of the human intestine. The
intestine-on-chip presented here is based on the design of Emulate
Inc, Boston, MA, USA.</p></caption><graphic xlink:href="10.1177_2050640619836057-fig3"></graphic></fig></p>
<p>In accordance with the morphological changes, the transcriptional profile of
epithelial cells cultured in the dynamic chip system is very different from that
of cells cultured in static Transwell systems or compared with HIO. In fact, the
intestine-on-chip profile most resembles the profile of the corresponding in
vivo intestinal segment.<sup><xref ref-type="bibr" rid="bibr58-2050640619836057">58</xref>,<xref ref-type="bibr" rid="bibr60-2050640619836057">60</xref></sup></p>
<p>The material most often used for chip fabrication, polydimethylsiloxane, is fully
transparent, making the chip readily amenable to microscopy. For research
purposes, sophisticated intestine-on-chip systems can be engineered to contain
sensors, for example to measure TEER.<sup><xref ref-type="bibr" rid="bibr61-2050640619836057">61</xref></sup> Integrated sensors are a major step forward because they allow for
continuous monitoring of the system, something that is very difficult and
laborious in conventional culture systems.</p>
</sec>
<sec id="sec11-2050640619836057">
<title>hiPSCs, HIOs and intestine-on-chip to model CeD</title>
<p>In contrast to monogenic diseases in which a single gene is involved, genetic
modeling of complex diseases like CeD requires the inclusion of the many
disease-associated genetic risk factors that need to be studied in the
disease-relevant cell or tissue.<sup><xref ref-type="bibr" rid="bibr19-2050640619836057">19</xref></sup> Combining hiPSC and HIO technology, in vitro models of the intestine can
be created from cells that contain the spectrum of CeD-associated genetic risk
factors (<xref ref-type="table" rid="table1-2050640619836057">Table 1</xref>).
Because hiPSC lines can be generated from relatively easily accessible somatic
cells such as urine-derived epithelial cells, skin-derived fibroblasts or
blood-derived erythroblasts,<sup><xref ref-type="bibr" rid="bibr48-2050640619836057">48</xref></sup> there is no dependency on intestinal biopsy material obtained by invasive
endoscopic procedures (in the case of CeD). This facilitates the collection of
starting material from both patients and healthy individuals. Varied genetic
backgrounds can then be studied to contrast the disease genetic background with
low risk backgrounds (<xref ref-type="fig" rid="fig4-2050640619836057">Figure
4</xref>). To study specific elements of the disease process, like barrier
function, genetic engineering can be used to perturb the system by creating
extreme genotypes (i.e. gene knock-out by CRISPR/Cas9 technology). These
technologies could be used to generate isogenic hiPSC lines that contain
identical genetic background, except for, for instance, one repaired
CeD-associated genetic risk factor. Such isogenic lines may reveal the
functional consequences of a single genetic variation associated with CeD. Using
hiPSCs as a starting point, the effect of a disease-associated genotype can be
evaluated in multiple disease-relevant cell types, either individually or in
combination, in an intestine-on-chip. This model is unique because it integrates
(1) the CeD-associated genetic background, (2) the interaction between
disease-relevant cell types, (3) any relevant environmental stimuli and (4) the
physical microenvironment of the intestine in a complex yet controllable manner.
Very recently, proof-of-concept was provided for an hiPSC-derived intestinal epithelial-layer-on-chip.<sup><xref ref-type="bibr" rid="bibr59-2050640619836057">59</xref></sup> This system now needs to be adapted toward a more CeD-relevant model that
includes hiPSC-derived endothelial<sup><xref ref-type="bibr" rid="bibr62-2050640619836057">62</xref></sup> and immune cells.<sup><xref ref-type="bibr" rid="bibr63-2050640619836057">63</xref><xref ref-type="bibr" rid="bibr64-2050640619836057"></xref>–<xref ref-type="bibr" rid="bibr65-2050640619836057">65</xref></sup>
<fig id="fig4-2050640619836057" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>The steps from patient or healthy individual to human induced
pluripotent stem cell (hiPSC)-derived intestinal organoids and
intestinal barrier-on-chip. The large population and patient
biobanks that have been constructed worldwide contain genomic data
and stored biological material, which allow for the selection of
patient and healthy control material based on genetic makeup. hiPSCs
can be derived from stored kidney epithelial cells from urine or
from erythroblasts from stored peripheral blood mononuclear cell
fractions. These materials are obtained in a minimally invasive
manner. The hiPSC lines can then be differentiated into human
intestinal organoids (HIOs), which can subsequently be seeded on a
microfluidic intestine-on-chip system to form an
intestinal-barrier-on-chip. Specific genetic factors can be studied
by genetic engineering of hiPSCs using CRISPR/Cas9 technology. For
example, CeD-associated risk alleles can be reverted to protective
alleles.</p></caption><graphic xlink:href="10.1177_2050640619836057-fig4"></graphic></fig></p>
</sec>
</sec>
<sec id="sec12-2050640619836057">
<title>Future outlook</title>
<sec id="sec13-2050640619836057">
<title>Improved understanding of CeD etiology</title>
<p>A CeD intestine-on-chip model can help address significant questions. It will
allow the investigation of the interaction between IELs and IECs in the presence
or absence of triggering environmental factors. In particular, the IL-15
expression by IECs implicated in activation of IELs<sup><xref ref-type="bibr" rid="bibr14-2050640619836057">14</xref></sup> can be monitored in response to these different stimuli. A possible
primary defect in intestinal barrier function, which in turn alters gluten
transport, can be addressed using different assays in a simple system in which
iPSC-derived IECs are present outside the immune context (<xref ref-type="fig" rid="fig5-2050640619836057">Figure 5(a)</xref>). With this system, genes
involved in the process can be identified. The role of the gut microbiome in CeD
pathogenesis can also be studied. One can envision that the microbiota affects
barrier function, but also that CeD-associated genetics affect microbiome
homeostasis by altering the immune response. Finally, the effect of different
environmental factors can be studied by introducing them into the system, for
instance introducing viral ligands, metabolites produced by CeD-associated
microbiota, or ATIs. The complexity of the system can be also adjusted to fit
the research question, ranging from one cell type to more complex systems (<xref ref-type="fig" rid="fig5-2050640619836057">Figure 5(b)</xref>). <fig id="fig5-2050640619836057" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Research opportunities using a human induced pluripotent stem cell
(hiPSC)-derived intestine-on-chip. (a) Functioning of the intestinal
epithelial barrier in patients with celiac disease (CeD) can be
assessed with the intestine-on-chip system by performing different
assays: (1) Tight junctions and adherence junctions can be labeled
and visualized on-chip using microscopy. (2) Barrier permeability
can be assessed by measuring transepithelial passing of fluorescein
isothiocyanate (FITC)-dextran complexes. (3) Barrier integrity can
be tested by incorporating electrodes on-chip to measure
transepithelial electrical resistance (TEER). (4) The passing of
gluten peptides across the barrier and the direct effect of gluten
peptides on the intestinal epithelial cells can be analyzed. (5) The
effect of CeD-associated cytokines on the barrier can be analyzed by
introducing the cytokines at the basolateral side (bottom channel).
(b) Integration of gut microbiome, endothelial cells and immune
cells in the intestine-on-chip. hiPSC-derived epithelial
layers-on-chip can be extended with microbiomes from CeD patients or
healthy controls on the apical side to assess the interactions
between the epithelial layer and bacteria. hiPSC-derived endothelial
cells can be introduced at the basolateral side to mimic the
vascular system. Additionally, peripheral blood mononuclear cell
(PBMC)- or hiPSC-derived immune cells can be introduced at the
basolateral side to mimic the immune system.</p></caption><graphic xlink:href="10.1177_2050640619836057-fig5"></graphic></fig></p>
</sec>
<sec id="sec14-2050640619836057">
<title>Development and testing of novel treatments</title>
<p>A lifelong adherence to a gluten-free diet has a profound impact on everyday
life, which makes treatments to inhibit the strong pro-inflammatory immune
response to gluten very valuable. A physiologically relevant CeD
intestine-on-chip model can be used to test novel drug candidates and existing
drugs for repositioning. By using patient-derived hiPSCs, differences in genetic
background that may affect drug efficacy can be taken into account. To be used
for drug screening and/or addressing pharmacogenetic questions, high-throughput
systems should be developed, as current devices are still low throughput and costly.<sup><xref ref-type="bibr" rid="bibr66-2050640619836057">66</xref></sup> Nevertheless, an intestine-on-chip has great potential for personalized
medicine, providing a model that can include an individual's genetic background,
relevant cell types and environmental triggers.</p>
</sec>
<sec id="sec15-2050640619836057">
<title>Toward a patient-on-chip</title>
<p>Although CeD is regarded as a disease of the intestine, the disease presents systemically.<sup><xref ref-type="bibr" rid="bibr6-2050640619836057">6</xref></sup> To capture the extraintestinal phenotypes, different organ-on-chip
systems could be coupled in the future. In the context of CeD, a first expansion
might be to couple an intestine-on-chip to a brain-on-chip. The
intestine-brain-axis is of particular interest because the clinical spectrum of
CeD includes behavioral changes such as anxiety, depression and
fatigue.<sup><xref ref-type="bibr" rid="bibr67-2050640619836057">67</xref>,<xref ref-type="bibr" rid="bibr68-2050640619836057">68</xref></sup> The mechanism underlying this “cross-talk” between
intestine and brain is poorly understood, but proposed explanations include the
interaction of gluten peptides with endorphin receptors in the brain, the
migration of activated immune cells to the brain<sup><xref ref-type="bibr" rid="bibr69-2050640619836057">69</xref></sup> and detrimental effects of circulating microbial metabolites<sup><xref ref-type="bibr" rid="bibr70-2050640619836057">70</xref>,<xref ref-type="bibr" rid="bibr71-2050640619836057">71</xref></sup>—all
processes that could be tested by linking organ-on-chip systems.</p>
</sec>
</sec>
<sec id="sec16-2050640619836057" sec-type="conclusions">
<title>Conclusion</title>
<p>The development of a CeD-specific intestine-on-chip model that closely recapitulates
human intestinal physiology will enable in vitro studies of CeD etiology in a near
in vivo situation. This will yield new insights into the role of genetic and
environmental factors in CeD and may accelerate the search for novel treatments.
Because genetic differences among CeD patients could be taken into account in the
development of novel treatments, the efficacy of a treatment could be more
accurately predicted for each individual. Moreover, this technology may improve
diagnostic capacity by identifying new diagnostic markers for individuals at high
risk for CeD.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors thank Kate Mc Intyre for editing the manuscript.</p>
</ack>
<sec id="sec17-2050640619836057">
<title>Declaration of conflicting interests</title>
<p>None declared.</p>
</sec>
<sec id="sec18-2050640619836057">
<title>Funding</title>
<p>This work was supported by a European Research Council advanced grant
(FP7/2007-2013/ERC Advanced Grant Agreement 2012-322698), an NWO Spinoza Prize (NWO
SPI 92-266), the NWO Gravitation Netherlands Organ-on-Chip Initiative (024.003.001)
and the United European Gastroenterology Research Prize to C.W. and a PhD
scholarship from the Graduate School of Medical Sciences, University of Groningen,
to J.M.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-2050640619836057">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biagi</surname><given-names>F</given-names></name><name><surname>Klersy</surname><given-names>C</given-names></name><name><surname>Balduzzi</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<article-title>Are we not over-estimating the prevalence of coeliac disease in
the general population?</article-title>. <source/>Ann Med
<year>2010</year>; <volume>42</volume>:
<fpage>557</fpage>–<lpage>561</lpage>.<pub-id pub-id-type="pmid">20883139</pub-id></mixed-citation>
</ref>
<ref id="bibr2-2050640619836057">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouziat</surname><given-names>R</given-names></name><name><surname>Hinterleitner</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>JJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Reovirus infection triggers inflammatory responses to dietary
antigens and development of celiac disease</article-title>.
<source/>Science
<year>2017</year>; <volume>356</volume>:
<fpage>44</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">28386004</pub-id></mixed-citation>
</ref>
<ref id="bibr3-2050640619836057">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Pujato</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Transcription factors operate across disease loci, with
<italic>EBNA2</italic> implicated in autoimmunity</article-title>.
<source/>Nat Genet
<year>2018</year>; <volume>50</volume>:
<fpage>699</fpage>–<lpage>707</lpage>.<pub-id pub-id-type="pmid">29662164</pub-id></mixed-citation>
</ref>
<ref id="bibr4-2050640619836057">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caminero</surname><given-names>A</given-names></name><name><surname>Galipeau</surname><given-names>HJ</given-names></name><name><surname>McCarville</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group>
<article-title>Duodenal bacteria from patients with celiac disease and healthy
subjects distinctly affect gluten breakdown and
immunogenicity</article-title>. <source/>Gastroenterology
<year>2016</year>; <volume>151</volume>:
<fpage>670</fpage>–<lpage>683</lpage>.<pub-id pub-id-type="pmid">27373514</pub-id></mixed-citation>
</ref>
<ref id="bibr5-2050640619836057">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spijkerman</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>IL</given-names></name><name><surname>Kolkman</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group>
<article-title>A large variety of clinical features and concomitant disorders in
celiac disease—A cohort study in the Netherlands</article-title>.
<source/>Dig Liver Dis
<year>2016</year>; <volume>48</volume>:
<fpage>499</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">26854256</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2050640619836057">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leffler</surname><given-names>DA</given-names></name><name><surname>Green</surname><given-names>PHR</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name></person-group>
<article-title>Extraintestinal manifestations of coeliac
disease</article-title>. <source/>Nat Rev Gastroenterol Hepatol
<year>2015</year>; <volume>12</volume>:
<fpage>561</fpage>–<lpage>571</lpage>.<pub-id pub-id-type="pmid">26260366</pub-id></mixed-citation>
</ref>
<ref id="bibr7-2050640619836057">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Berti</surname><given-names>I</given-names></name><name><surname>Gerarduzzi</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>Prevalence of celiac disease in at-risk and non-at-risk groups in
the United States</article-title>. <source/>Arch Intern Med
<year>2003</year>; <volume>163</volume>:
<fpage>286</fpage>–<lpage>292</lpage>.<pub-id pub-id-type="pmid">12578508</pub-id></mixed-citation>
</ref>
<ref id="bibr8-2050640619836057">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>JF</given-names></name><name><surname>Bai</surname><given-names>JC</given-names></name><name><surname>Biagi</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Diagnosis and management of adult coeliac disease: Guidelines
from the British Society of Gastroenterology</article-title>.
<source/>Gut
<year>2014</year>; <volume>63</volume>:
<fpage>1210</fpage>–<lpage>1228</lpage>.<pub-id pub-id-type="pmid">24917550</pub-id></mixed-citation>
</ref>
<ref id="bibr9-2050640619836057">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Newman</surname><given-names>JM</given-names></name></person-group>
<article-title>Celiac diet: Its impact on quality of
life</article-title>. <source/>J Am Diet Assoc
<year>2003</year>; <volume>103</volume>:
<fpage>1533</fpage>–<lpage>1535</lpage>.<pub-id pub-id-type="pmid">14576723</pub-id></mixed-citation>
</ref>
<ref id="bibr10-2050640619836057">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Molberg</surname><given-names>Ø</given-names></name><name><surname>Parrot</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<article-title>Structural basis for gluten intolerance in celiac
sprue</article-title>. <source/>Science
<year>2002</year>; <volume>297</volume>:
<fpage>2275</fpage>–<lpage>2279</lpage>.<pub-id pub-id-type="pmid">12351792</pub-id></mixed-citation>
</ref>
<ref id="bibr11-2050640619836057">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname><given-names>M</given-names></name><name><surname>Siegmund</surname><given-names>B</given-names></name><name><surname>Schulzke</surname><given-names>JD</given-names></name><etal>et al.</etal></person-group>
<article-title>Celiac disease: Role of the epithelial barrier</article-title>.
<source/>Cell Mol Gastroenterol Hepatol
<year>2017</year>; <volume>3</volume>:
<fpage>150</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">28275682</pub-id></mixed-citation>
</ref>
<ref id="bibr12-2050640619836057">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabri</surname><given-names>B</given-names></name><name><surname>Sollid</surname><given-names>LM</given-names></name></person-group>
<article-title>T cells in celiac disease</article-title>.
<source/>J Immunol
<year>2017</year>; <volume>198</volume>:
<fpage>3005</fpage>–<lpage>3014</lpage>.<pub-id pub-id-type="pmid">28373482</pub-id></mixed-citation>
</ref>
<ref id="bibr13-2050640619836057">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sollid</surname><given-names>LM</given-names></name><name><surname>Molberg McAdam</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Autoantibodies in coeliac disease: Tissue transglutaminase—Guilt
by association?</article-title>. <source/>Gut
<year>1997</year>; <volume>41</volume>:
<fpage>851</fpage>–<lpage>852</lpage>.<pub-id pub-id-type="pmid">9462222</pub-id></mixed-citation>
</ref>
<ref id="bibr14-2050640619836057">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abadie</surname><given-names>V</given-names></name><name><surname>Discepolo</surname><given-names>V</given-names></name><name><surname>Jabri</surname><given-names>B</given-names></name></person-group>
<article-title>Intraepithelial lymphocytes in celiac disease
immunopathology</article-title>. <source/>Semin Immunopathol
<year>2012</year>; <volume>34</volume>:
<fpage>551</fpage>–<lpage>556</lpage>.<pub-id pub-id-type="pmid">22660791</pub-id></mixed-citation>
</ref>
<ref id="bibr15-2050640619836057">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>MA</given-names></name><name><surname>Lindenbergh-Kortleve</surname><given-names>DJ</given-names></name><name><surname>Raatgeep</surname><given-names>HC</given-names></name><etal>et al.</etal></person-group>
<article-title>Increased production of interleukin-21, but not interleukin-17A,
in the small intestine characterizes pediatric celiac
disease</article-title>. <source/>Mucosal Immunol
<year>2013</year>; <volume>6</volume>:
<fpage>1202</fpage>–<lpage>1213</lpage>.<pub-id pub-id-type="pmid">23571506</pub-id></mixed-citation>
</ref>
<ref id="bibr16-2050640619836057">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name></person-group>
<article-title>Genetic testing: Who should do the testing and
what is the role of genetic testing in the setting of celiac
disease?</article-title>. <source/>Gastroenterology
<year>2005</year>; <volume>128</volume>:
<fpage>33</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">15633121</pub-id></mixed-citation>
</ref>
<ref id="bibr17-2050640619836057">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trynka</surname><given-names>G</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name></person-group>
<article-title>A genetic perspective on coeliac
disease</article-title>. <source/>Trends Mol Med
<year>2010</year>; <volume>16</volume>:
<fpage>537</fpage>–<lpage>550</lpage>.<pub-id pub-id-type="pmid">20947431</pub-id></mixed-citation>
</ref>
<ref id="bibr18-2050640619836057">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trynka</surname><given-names>G</given-names></name><name><surname>Hunt</surname><given-names>KA</given-names></name><name><surname>Bockett</surname><given-names>NA</given-names></name><etal>et al.</etal></person-group>
<article-title>Dense genotyping identifies and localizes multiple common and
rare variant association signals in celiac disease</article-title>.
<source/>Nat Genet
<year>2011</year>; <volume>43</volume>:
<fpage>1193</fpage>–<lpage>1201</lpage>.<pub-id pub-id-type="pmid">22057235</pub-id></mixed-citation>
</ref>
<ref id="bibr19-2050640619836057">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Withoff</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jonkers</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<article-title>Understanding celiac disease by genomics</article-title>.
<source/>Trends Genet
<year>2016</year>; <volume>32</volume>:
<fpage>295</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">26972670</pub-id></mixed-citation>
</ref>
<ref id="bibr20-2050640619836057">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Gutierrez-Achury</surname><given-names>J</given-names></name><name><surname>Kanduri</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Systematic annotation of celiac disease loci refines pathological
pathways and suggests a genetic explanation for increased interferon-gamma
levels</article-title>. <source/>Hum Mol Genet
<year>2015</year>; <volume>24</volume>:
<fpage>397</fpage>–<lpage>409</lpage>.<pub-id pub-id-type="pmid">25190711</pub-id></mixed-citation>
</ref>
<ref id="bibr21-2050640619836057">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junker</surname><given-names>Y</given-names></name><name><surname>Zeissig</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Wheat amylase trypsin inhibitors drive intestinal inflammation
via activation of toll-like receptor 4</article-title>. <source/>J Exp
Med
<year>2012</year>; <volume>209</volume>:
<fpage>2395</fpage>–<lpage>2408</lpage>.<pub-id pub-id-type="pmid">23209313</pub-id></mixed-citation>
</ref>
<ref id="bibr22-2050640619836057">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stene</surname><given-names>LC</given-names></name><name><surname>Honeyman</surname><given-names>MC</given-names></name><name><surname>Hoffenberg</surname><given-names>EJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Rotavirus infection frequency and risk of celiac disease
autoimmunity in early childhood: A longitudinal study</article-title>.
<source/>Am J Gastroenterol
<year>2006</year>; <volume>101</volume>:
<fpage>2333</fpage>–<lpage>2340</lpage>.<pub-id pub-id-type="pmid">17032199</pub-id></mixed-citation>
</ref>
<ref id="bibr23-2050640619836057">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plot</surname><given-names>L</given-names></name><name><surname>Amital</surname><given-names>H</given-names></name></person-group>
<article-title>Infectious associations of celiac
disease</article-title>. <source/>Autoimmun Rev
<year>2009</year>; <volume>8</volume>:
<fpage>316</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">18973831</pub-id></mixed-citation>
</ref>
<ref id="bibr24-2050640619836057">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collado</surname><given-names>MC</given-names></name><name><surname>Calabuig</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>Y</given-names></name></person-group>
<article-title>Differences between the fecal microbiota of
coeliac infants and healthy controls</article-title>. <source/>Curr Issues
Intest Microbiol
<year>2007</year>; <volume>8</volume>:
<fpage>9</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">17489434</pub-id></mixed-citation>
</ref>
<ref id="bibr25-2050640619836057">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caminero</surname><given-names>A</given-names></name><name><surname>Meisel</surname><given-names>M</given-names></name><name><surname>Jabri</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>Mechanisms by which gut microorganisms influence food
sensitivities</article-title>. <source/>Nat Rev Gastroenterol
Hepatol
<year>2019</year>; <volume>16</volume>:
<fpage>7</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">30214038</pub-id></mixed-citation>
</ref>
<ref id="bibr26-2050640619836057">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nistal</surname><given-names>E</given-names></name><name><surname>Caminero</surname><given-names>A</given-names></name><name><surname>Herrán</surname><given-names>AR</given-names></name><etal>et al.</etal></person-group>
<article-title>Differences of small intestinal bacteria populations in adults
and children with/without celiac disease: Effect of age, gluten diet, and
disease</article-title>. <source/>Inflamm Bowel Dis
<year>2012</year>; <volume>18</volume>:
<fpage>649</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">21826768</pub-id></mixed-citation>
</ref>
<ref id="bibr27-2050640619836057">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivares</surname><given-names>M</given-names></name><name><surname>Neef</surname><given-names>A</given-names></name><name><surname>Castillejo</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>The HLA-DQ2 genotype selects for early intestinal microbiota
composition in infants at high risk of developing coeliac
disease</article-title>. <source/>Gut
<year>2015</year>; <volume>64</volume>:
<fpage>406</fpage>–<lpage>417</lpage>.<pub-id pub-id-type="pmid">24939571</pub-id></mixed-citation>
</ref>
<ref id="bibr28-2050640619836057">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>G</given-names></name><name><surname>Nadal</surname><given-names>I</given-names></name><name><surname>Collado</surname><given-names>MC</given-names></name><etal>et al.</etal></person-group>
<article-title>Effects of a gluten-free diet on gut microbiota and immune
function in healthy adult human subjects</article-title>. <source/>Br J
Nutr
<year>2009</year>; <volume>102</volume>:
<fpage>1154</fpage>–<lpage>1160</lpage>.<pub-id pub-id-type="pmid">19445821</pub-id></mixed-citation>
</ref>
<ref id="bibr29-2050640619836057">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonder</surname><given-names>MJ</given-names></name><name><surname>Tigchelaar</surname><given-names>EF</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><etal>et al.</etal></person-group>
<article-title>The influence of a short-term gluten-free diet on the human gut
microbiome</article-title>. <source/>Genome Med
<year>2016</year>; <volume>8</volume>:
<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">26750923</pub-id></mixed-citation>
</ref>
<ref id="bibr30-2050640619836057">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caminero</surname><given-names>A</given-names></name><name><surname>Herrán</surname><given-names>AR</given-names></name><name><surname>Nistal</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Diversity of the cultivable human gut microbiome involved in
gluten metabolism: Isolation of microorganisms with potential interest for
coeliac disease</article-title>. <source/>FEMS Microbiol Ecol
<year>2014</year>; <volume>88</volume>:
<fpage>309</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">24499426</pub-id></mixed-citation>
</ref>
<ref id="bibr31-2050640619836057">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galipeau</surname><given-names>HJ</given-names></name><name><surname>McCarville</surname><given-names>JL</given-names></name><name><surname>Huebener</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Intestinal microbiota modulates gluten-induced immunopathology in
humanized mice</article-title>. <source/>Am J Pathol
<year>2015</year>; <volume>185</volume>:
<fpage>2969</fpage>–<lpage>2982</lpage>.<pub-id pub-id-type="pmid">26456581</pub-id></mixed-citation>
</ref>
<ref id="bibr32-2050640619836057">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Elburg</surname><given-names>RM</given-names></name><name><surname>Uil</surname><given-names>JJ</given-names></name><name><surname>Mulder</surname><given-names>CJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Intestinal permeability in patients with coeliac disease and
relatives of patients with coeliac disease</article-title>.
<source/>Gut
<year>1993</year>; <volume>34</volume>:
<fpage>354</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">8472983</pub-id></mixed-citation>
</ref>
<ref id="bibr33-2050640619836057">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smecuol</surname><given-names>E</given-names></name><name><surname>Bai</surname><given-names>JC</given-names></name><name><surname>Vazquez</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Gastrointestinal permeability in celiac disease</article-title>.
<source/>Gastroenterology
<year>1997</year>; <volume>112</volume>:
<fpage>1129</fpage>–<lpage>1136</lpage>.<pub-id pub-id-type="pmid">9097995</pub-id></mixed-citation>
</ref>
<ref id="bibr34-2050640619836057">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelsang</surname><given-names>H</given-names></name><name><surname>Schwarzenhofer</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>In vivo and in vitro permeability in coeliac
disease</article-title>. <source/>Aliment Pharmacol Ther
<year>2001</year>; <volume>15</volume>:
<fpage>1417</fpage>–<lpage>1425</lpage>.<pub-id pub-id-type="pmid">11552914</pub-id></mixed-citation>
</ref>
<ref id="bibr35-2050640619836057">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulzke</surname><given-names>J-D</given-names></name><name><surname>Bentzel</surname><given-names>CJ</given-names></name><name><surname>Schulzke</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<article-title>Epithelial tight junction structure in the jejunum of children
with acute and treated celiac sprue</article-title>. <source/>Pediatr
Res
<year>1998</year>; <volume>43</volume>:
<fpage>435</fpage>–<lpage>441</lpage>.<pub-id pub-id-type="pmid">9544995</pub-id></mixed-citation>
</ref>
<ref id="bibr36-2050640619836057">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname><given-names>M</given-names></name><name><surname>Günzel</surname><given-names>D</given-names></name><name><surname>Buergel</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Cell polarity-determining proteins Par-3 and PP-1 are involved in
epithelial tight junction defects in coeliac disease</article-title>.
<source/>Gut
<year>2012</year>; <volume>61</volume>:
<fpage>220</fpage>–<lpage>228</lpage>.<pub-id pub-id-type="pmid">21865402</pub-id></mixed-citation>
</ref>
<ref id="bibr37-2050640619836057">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marietta</surname><given-names>EV</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>JA</given-names></name></person-group>
<article-title>In vitro and in vivo models of celiac
disease</article-title>. <source/>Expert Opin Drug Discov
<year>2009</year>; <volume>4</volume>:
<fpage>1113</fpage>–<lpage>1123</lpage>.<pub-id pub-id-type="pmid">23480432</pub-id></mixed-citation>
</ref>
<ref id="bibr38-2050640619836057">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoven</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>JA</given-names></name><name><surname>Marietta</surname><given-names>EV</given-names></name></person-group>
<article-title>Latest in vitro and in vivo models of celiac
disease</article-title>. <source/>Expert Opin Drug Discov
<year>2014</year>; <volume>8</volume>:
<fpage>445</fpage>–<lpage>457</lpage>.</mixed-citation>
</ref>
<ref id="bibr39-2050640619836057">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Huh</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>Human gut-on-a-chip inhabited by microbial flora that experiences
intestinal peristalsis-like motions and flow</article-title>. <source/>Lab
Chip
<year>2012</year>; <volume>12</volume>:
<fpage>2165</fpage>–<lpage>2174</lpage>.<pub-id pub-id-type="pmid">22434367</pub-id></mixed-citation>
</ref>
<ref id="bibr40-2050640619836057">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePaolo</surname><given-names>RW</given-names></name><name><surname>Abadie</surname><given-names>V</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Co-adjuvant effects of retinoic acid and IL-15 induce
inflammatory immunity to dietary antigens</article-title>.
<source/>Nature
<year>2011</year>; <volume>471</volume>:
<fpage>220</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">21307853</pub-id></mixed-citation>
</ref>
<ref id="bibr41-2050640619836057">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>N</given-names></name><name><surname>Hiroi</surname><given-names>T</given-names></name><name><surname>Kweon</surname><given-names>MN</given-names></name><etal>et al.</etal></person-group>
<article-title>IL-15-dependent activation-induced cell death-resistant Th1 type
CD8 + NK1.1 + T cells for the development of small intestinal
inflammation</article-title>. <source/>J Immunol
<year>2002</year>; <volume>169</volume>:
<fpage>460</fpage>–<lpage>468</lpage>.<pub-id pub-id-type="pmid">12077277</pub-id></mixed-citation>
</ref>
<ref id="bibr42-2050640619836057">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korneychuk</surname><given-names>N</given-names></name><name><surname>Ramiro-Puig</surname><given-names>E</given-names></name><name><surname>Ettersperger</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Interleukin 15 and CD4 + T cells cooperate to promote small
intestinal enteropathy in response to dietary antigen</article-title>.
<source/>Gastroenterology
<year>2014</year>; <volume>146</volume>:
<fpage>1017</fpage>–<lpage>1027</lpage>.<pub-id pub-id-type="pmid">24361466</pub-id></mixed-citation>
</ref>
<ref id="bibr43-2050640619836057">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TL</given-names></name><name><surname>Vieira-Silva</surname><given-names>S</given-names></name><name><surname>Liston</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>How informative is the mouse for human gut microbiota
research?</article-title>. <source/>Dis Model Mech
<year>2015</year>; <volume>8</volume>:
<fpage>1</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">25561744</pub-id></mixed-citation>
</ref>
<ref id="bibr44-2050640619836057">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestas</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>CC</given-names></name></person-group>
<article-title>Of mice and not men: Differences between mouse
and human immunology</article-title>. <source/>J Immunol
<year>2004</year>; <volume>172</volume>:
<fpage>2731</fpage>–<lpage>2738</lpage>.<pub-id pub-id-type="pmid">14978070</pub-id></mixed-citation>
</ref>
<ref id="bibr45-2050640619836057">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Bäckhed</surname><given-names>F</given-names></name><name><surname>Turnbaugh</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Obesity alters gut microbial ecology</article-title>.
<source/>Proc Natl Acad Sci U S A
<year>2005</year>; <volume>102</volume>:
<fpage>11070</fpage>–<lpage>11075</lpage>.<pub-id pub-id-type="pmid">16033867</pub-id></mixed-citation>
</ref>
<ref id="bibr46-2050640619836057">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group>
<article-title>Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors</article-title>.
<source/>Cell
<year>2006</year>; <volume>126</volume>:
<fpage>663</fpage>–<lpage>676</lpage>.<pub-id pub-id-type="pmid">16904174</pub-id></mixed-citation>
</ref>
<ref id="bibr47-2050640619836057">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Ohnuki</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts
by defined factors</article-title>. <source/>Cell
<year>2007</year>; <volume>131</volume>:
<fpage>861</fpage>–<lpage>872</lpage>.<pub-id pub-id-type="pmid">18035408</pub-id></mixed-citation>
</ref>
<ref id="bibr48-2050640619836057">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raab</surname><given-names>S</given-names></name><name><surname>Klingenstein</surname><given-names>M</given-names></name><name><surname>Liebau</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>A comparative view on human somatic cell sources for iPSC
generation</article-title>. <source/>Stem Cells Int
<year>2014</year>; <volume>2014</volume>:
<fpage>768391</fpage>.<pub-id pub-id-type="pmid">25431601</pub-id></mixed-citation>
</ref>
<ref id="bibr49-2050640619836057">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>Ferrante</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Long-term expansion of epithelial organoids from human colon,
adenoma, adenocarcinoma, and Barrett's epithelium</article-title>.
<source/>Gastroenterology
<year>2011</year>; <volume>141</volume>:
<fpage>1762</fpage>–<lpage>1772</lpage>.<pub-id pub-id-type="pmid">21889923</pub-id></mixed-citation>
</ref>
<ref id="bibr50-2050640619836057">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretzschmar</surname><given-names>K</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>
<article-title>Organoids: Modeling development and the stem
cell niche in a dish</article-title>. <source/>Dev Cell
<year>2016</year>; <volume>38</volume>:
<fpage>590</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">27676432</pub-id></mixed-citation>
</ref>
<ref id="bibr51-2050640619836057">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fordham</surname><given-names>RP</given-names></name><name><surname>Yui</surname><given-names>S</given-names></name><name><surname>Hannan</surname><given-names>NR</given-names></name><etal>et al.</etal></person-group>
<article-title>Transplantation of expanded fetal intestinal progenitors
contributes to colon regeneration after injury</article-title>. <source/>Cell
Stem Cell
<year>2013</year>; <volume>13</volume>:
<fpage>734</fpage>–<lpage>744</lpage>.<pub-id pub-id-type="pmid">24139758</pub-id></mixed-citation>
</ref>
<ref id="bibr52-2050640619836057">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>JR</given-names></name><name><surname>Mayhew</surname><given-names>CN</given-names></name><name><surname>Rankin</surname><given-names>SA</given-names></name><etal>et al.</etal></person-group>
<article-title>Directed differentiation of human pluripotent stem cells into
intestinal tissue in vitro</article-title>. <source/>Nature
<year>2011</year>; <volume>470</volume>:
<fpage>105</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">21151107</pub-id></mixed-citation>
</ref>
<ref id="bibr53-2050640619836057">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>SN</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name></person-group>
<article-title>Microfluidic organs-on-chips</article-title>.
<source/>Nat Biotechnol
<year>2014</year>; <volume>32</volume>:
<fpage>760</fpage>–<lpage>772</lpage>.<pub-id pub-id-type="pmid">25093883</pub-id></mixed-citation>
</ref>
<ref id="bibr54-2050640619836057">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Manfrin</surname><given-names>A</given-names></name><name><surname>Lutolf</surname><given-names>MP</given-names></name></person-group>
<article-title>Progress and potential in organoid
research</article-title>. <source/>Nat Rev Genet
<year>2018</year>; <volume>19</volume>:
<fpage>671</fpage>–<lpage>687</lpage>.<pub-id pub-id-type="pmid">30228295</pub-id></mixed-citation>
</ref>
<ref id="bibr55-2050640619836057">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartfeld</surname><given-names>S</given-names></name><name><surname>Bayram</surname><given-names>T</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>In vitro expansion of human gastric epithelial stem cells and
their responses to bacterial infection</article-title>.
<source/>Gastroenterology
<year>2015</year>; <volume>148</volume>:
<fpage>126</fpage>–<lpage>136</lpage>.<pub-id pub-id-type="pmid">25307862</pub-id></mixed-citation>
</ref>
<ref id="bibr56-2050640619836057">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bein</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>W</given-names></name><name><surname>Jalili-Firoozinezhad</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Microfluidic organ-on-a-chip models of human
intestine</article-title>. <source/>Cell Mol Gastroenterol Hepatol
<year>2018</year>; <volume>5</volume>:
<fpage>659</fpage>–<lpage>668</lpage>.<pub-id pub-id-type="pmid">29713674</pub-id></mixed-citation>
</ref>
<ref id="bibr57-2050640619836057">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Ingber</surname><given-names>D</given-names></name></person-group>
<article-title>Gut-on-a-chip microenvironment induces human
intestinal cells to undergo villus differentiation</article-title>.
<source/>Integr Biol
<year>2013</year>; <volume>5</volume>:
<fpage>1130</fpage>–<lpage>1140</lpage>.</mixed-citation>
</ref>
<ref id="bibr58-2050640619836057">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasendra</surname><given-names>M</given-names></name><name><surname>Tovaglieri</surname><given-names>A</given-names></name><name><surname>Sontheimer-Phelps</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Development of a primary human small intestine-on-a-chip using
biopsy-derived organoids</article-title>. <source/>Sci Rep
<year>2018</year>; <volume>8</volume>: <fpage>2871</fpage>.<pub-id pub-id-type="pmid">29440725</pub-id></mixed-citation>
</ref>
<ref id="bibr59-2050640619836057">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Workman</surname><given-names>M</given-names></name><name><surname>Gleeson</surname><given-names>J</given-names></name><name><surname>Troisi</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Enhanced utilization of induced pluripotent stem cell-derived
human intestinal organoids using microengineered chips</article-title>.
<source/>Cell Mol Gastroenterol Hepatol
<year>2018</year>; <volume>5</volume>:
<fpage>669</fpage>–<lpage>677</lpage>.<pub-id pub-id-type="pmid">29930984</pub-id></mixed-citation>
</ref>
<ref id="bibr60-2050640619836057">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Contributions of microbiome and mechanical deformation to
intestinal bacterial overgrowth and inflammation in a human
gut-on-a-chip</article-title>. <source/>Proc Natl Acad Sci U S A
<year>2016</year>; <volume>113</volume>:
<fpage>E7</fpage>–<lpage>E15</lpage>.<pub-id pub-id-type="pmid">26668389</pub-id></mixed-citation>
</ref>
<ref id="bibr61-2050640619836057">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arık</surname><given-names>YB</given-names></name><name><surname>van der Helm</surname><given-names>MW</given-names></name><name><surname>Odijk</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Barriers-on-chips: Measurement of barrier function of tissues in
organs-on-chips</article-title>. <source/>Biomicrofluidics
<year>2018</year>; <volume>12</volume>: <fpage>042218</fpage>.<pub-id pub-id-type="pmid">30018697</pub-id></mixed-citation>
</ref>
<ref id="bibr62-2050640619836057">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name></person-group>
<article-title>Generation of human pluripotent stem
cell-derived endothelial cells and their therapeutic
utility</article-title>. <source/>Curr Cardiol Rep
<year>2018</year>; <volume>20</volume>: <fpage>45</fpage>.<pub-id pub-id-type="pmid">29730842</pub-id></mixed-citation>
</ref>
<ref id="bibr63-2050640619836057">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wilgenburg</surname><given-names>B</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Vowles</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Efficient, long term production of monocyte-derived macrophages
from human pluripotent stem cells under partly-defined and fully-defined
conditions</article-title>. <source/>PLoS One
<year>2013</year>; <volume>8</volume>: <fpage>e71098</fpage>.<pub-id pub-id-type="pmid">23951090</pub-id></mixed-citation>
</ref>
<ref id="bibr64-2050640619836057">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senju</surname><given-names>S</given-names></name><name><surname>Haruta</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Generation of dendritic cells and macrophages from human induced
pluripotent stem cells aiming at cell therapy</article-title>. <source/>Gene
Ther
<year>2011</year>; <volume>18</volume>:
<fpage>874</fpage>–<lpage>883</lpage>.<pub-id pub-id-type="pmid">21430784</pub-id></mixed-citation>
</ref>
<ref id="bibr65-2050640619836057">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morishima</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Neutrophil differentiation from human-induced pluripotent stem
cells</article-title>. <source/>J Cell Physiol
<year>2011</year>; <volume>226</volume>:
<fpage>1283</fpage>–<lpage>1291</lpage>.<pub-id pub-id-type="pmid">20945397</pub-id></mixed-citation>
</ref>
<ref id="bibr66-2050640619836057">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Loskill</surname><given-names>P</given-names></name></person-group>
<article-title>High-throughput organ-on-a-chip systems: Current
status and remaining challenges</article-title>. <source/>Curr Opin Biomed
Eng
<year>2018</year>; <volume>6</volume>:
<fpage>33</fpage>–<lpage>41</lpage>.</mixed-citation>
</ref>
<ref id="bibr67-2050640619836057">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LB</given-names></name><name><surname>Lynch</surname><given-names>KF</given-names></name><name><surname>Kurppa</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Psychological manifestations of celiac disease autoimmunity in
young children</article-title>. <source/>Pediatrics
<year>2017</year>; <volume>139</volume>:
<fpage>e20162848</fpage>.<pub-id pub-id-type="pmid">28219962</pub-id></mixed-citation>
</ref>
<ref id="bibr68-2050640619836057">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zingone</surname><given-names>F</given-names></name><name><surname>Swift</surname><given-names>GL</given-names></name><name><surname>Card</surname><given-names>TR</given-names></name><etal>et al.</etal></person-group>
<article-title>Psychological morbidity of celiac disease: A review of the
literature</article-title>. <source/>United Eur Gastroenterol J
<year>2015</year>; <volume>3</volume>:
<fpage>136</fpage>–<lpage>145</lpage>.</mixed-citation>
</ref>
<ref id="bibr69-2050640619836057">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bressan</surname><given-names>P</given-names></name><name><surname>Kramer</surname><given-names>P</given-names></name></person-group>
<article-title>Bread and other edible agents of mental
disease</article-title>. <source/>Front Hum Neurosci
<year>2016</year>; <volume>10</volume>: <fpage>130</fpage>.<pub-id pub-id-type="pmid">27065833</pub-id></mixed-citation>
</ref>
<ref id="bibr70-2050640619836057">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>KV</given-names></name><name><surname>Sherwin</surname><given-names>E</given-names></name><name><surname>Schellekens</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Feeding the microbiota-gut-brain axis: Diet, microbiome, and
neuropsychiatry</article-title>. <source/>Transl Res
<year>2017</year>; <volume>179</volume>:
<fpage>223</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">27832936</pub-id></mixed-citation>
</ref>
<ref id="bibr71-2050640619836057">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>M</given-names></name><name><surname>Sapone</surname><given-names>A</given-names></name><name><surname>Senger</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Blood-brain barrier and intestinal epithelial barrier alterations
in autism spectrum disorders</article-title>. <source/>Mol Autism
<year>2016</year>; <volume>7</volume>: <fpage>49</fpage>.<pub-id pub-id-type="pmid">27957319</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>